Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
- Conditions
- Myelodysplastic SyndromesAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Northside Hospital, Inc.
- Registration Number
- NCT06337331
- Locations
- 🇺🇸
Caitlin Guzowski, Atlanta, Georgia, United States
Ma-Spore ALL 2020 Study
- Conditions
- B Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT06336395
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Kuala Lumpur, Malaysia
🇸🇬KK Women's and Children's Hospital, Singapore, Singapore
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
- Conditions
- ALL, ChildhoodMDSAML, ChildhoodHematologic MalignancyLymphoma
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT06326463
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
- Conditions
- Non-hodgkin Lymphoma
- Interventions
- Biological: TCR reserved and Power3 gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T)Drug: FludarabineDrug: Cyclophosphamide
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06323525
- Locations
- 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China
🇨🇳School of Life Sciences, Peking University, Beijing, China
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
- Conditions
- Non-hodgkin Lymphoma,B Cell
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06321289
- Locations
- 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳School of medicine, Tsinghua University & Changping Laboratory, Beijing, China
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
- Conditions
- CLL/SLL
- Interventions
- Drug: Lisaftoclax (APG-2575)Drug: FludarabineDrug: Cyclophosphamide，CTXDrug: AcalabrutinibDrug: RituximabDrug: Chlorambucil
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT06319456
- Locations
- 🇨🇳
Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
- Conditions
- Relapsed or Refractory Follicular Lymphoma
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Target Recruit Count
- 300
- Registration Number
- NCT06313996
FT819 in Moderate to Severe Active Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT06308978
- Locations
- 🇺🇸
University of Minnesota Medical School, Minneapolis, Minnesota, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
- Conditions
- Ovary NeoplasmEpithelial Ovarian CancerOvarian CancerRecurrent
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT06305299
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- Conditions
- Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- Biological: Actinium Ac 225-DOTA-DaratumumabProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyBiological: DaratumumabProcedure: EchocardiographyDrug: FludarabineProcedure: Hematopoietic Cell TransplantationBiological: Indium In 111-DOTA-DaratumumabDrug: MelphalanProcedure: Multigated Acquisition ScanProcedure: Radionuclide ImagingProcedure: Single Photon Emission Computed TomographyDrug: SirolimusDrug: TacrolimusRadiation: Total Marrow and Lymphoid Irradiation
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT06287944
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.